Pulmonary Arterial Hypertension Market

March 2021 | DMG00019A

The scope of this report covers the different drug classed used to treat pulmonary arterial hypertension along with the probable novel therapies used to cure the disease. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each drug class, route of administration, distribution channel, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional pulmonary arterial hypertension markets; it explains the major market drivers of the global pulmonary arterial hypertension industry, current trends within the industry, major applications, and the regional dynamics of the global pulmonary Arterial Hypertension Market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global pulmonary arterial hypertension market. Recent mergers and acquisitions, new product development is also catered in this report.

Report Includes

35 tables and 43 figures
An up-to-date analysis of the Global Pulmonary Arterial Hypertension Market.
Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
Estimation of market size and revenue forecast for Global Pulmonary Arterial Hypertension Market, and corresponding market share analysis by drug class, route of administration, distribution channel, and region.
Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Pulmonary Arterial Hypertension, identification of the companies that are best positioned to meet this demand.
In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
Identification of promising new therapies, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
Impact of COVID-19 on the Pulmonary Arterial Hypertension Market as compared to overall global economy.
Insight into the growth development strategies of major Pulmonary Arterial Hypertension manufacturers and their key competitive landscape
Descriptive company profiles of the leading market participants, Johnson & Johnson, Bayer AG, Pfizer, Inc., GlaxoSmithKline Plc., United Therapeutics Corporation, Gilead Sciences, Inc., and others.

Pulmonary Arterial Hypertension Market

Single User License: $2750

Enquiry Before Buying

Table 1 : Global Pulmonary Arterial Hypertension Market, Through 2026
Table 2 : Global Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
Table 3 : Global Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
Table 4 : Global Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
Table 5 : Global Pulmonary Arterial Hypertension Market, by Region, Through 2026
Table 6 : North America Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
Table 7 : North America Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
Table 8 : North America Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
Table 9 : North America Pulmonary Arterial Hypertension Market, by Country, Through 2026
Table 10 : Europe Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
Table 11 : Europe Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
Table 12 : Europe Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
Table 13 : Europe Pulmonary Arterial Hypertension Market, by Country, Through 2026
Table 14 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
Table 15 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
Table 16 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
Table 17 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Country, Through 2026
Table 18 : South America Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
Table 19 : South America Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
Table 20 : South America Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
Table 21 : South America Pulmonary Arterial Hypertension Market, by Country, Through 2026
Table 22 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Drug Class, Through 2026
Table 23 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration, Through 2026
Table 24 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel, Through 2026
Table 25 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Country, Through 2026
Table 26 : Johnson & Johnson: Financial Performance, Through 2020
Table 27 : Bayer AG: Financial Performance, Through 2020
Table 28 : Pfizer, Inc.: Financial Performance, Through 2020
Table 29 : GlaxoSmithKline Plc.: Financial Performance, Through 2020
Table 30 : United Therapeutics Corporation: Financial Performance, Through 2020
Table 31 : Gilead Sciences, Inc.: Financial Performance, Through 2020
Table 32 : Bristol-Myers Squibb Company: Financial Performance, Through 2020
Table 33 : Merck & Co. Inc.: Financial Performance, Through 2020
Table 34 : Daiichi Sankyo Company Limited: Financial Performance, Through 2020
Table 35 : Eli Lilly and Company: Financial Performance, Through 2020

Figure 1 : Global Pulmonary Arterial Hypertension Market
Figure 2 : Global Pulmonary Arterial Hypertension Market, by Value, 2019-2026
Figure 3 : Global Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
Figure 4 : Global Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
Figure 5 : Global Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
Figure 6 : Global Pulmonary Arterial Hypertension Market, by Value, by Region, 2020
Figure 7 : Global Pulmonary Arterial Hypertension Market, by Value, by Company, 2020
Figure 8 : Global Pulmonary Arterial Hypertension Market, Product Map, 2020
Figure 9 : North America Pulmonary Arterial Hypertension Market, by Value, 2019-2026
Figure 10 : North America Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
Figure 11 : North America Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
Figure 12 : North America Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
Figure 13 : North America Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
Figure 14 : Europe Pulmonary Arterial Hypertension Market, by Value, 2019-2026
Figure 15 : Europe Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
Figure 16 : Europe Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
Figure 17 : Europe Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
Figure 18 : Europe Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
Figure 19 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, 2019-2026
Figure 20 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
Figure 21 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
Figure 22 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
Figure 23 : Asia-Pacific Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
Figure 24 : South America Pulmonary Arterial Hypertension Market, by Value, 2019-2026
Figure 25 : South America Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
Figure 26 : South America Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
Figure 27 : South America Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
Figure 28 : South America Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
Figure 29 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, 2019-2026
Figure 30 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Drug Class, 2019-2026
Figure 31 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Route of Administration, 2019-2026
Figure 32 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Distribution Channel, 2019-2026
Figure 33 : Middle East & Africa Pulmonary Arterial Hypertension Market, by Value, by Country, 2020
Figure 34 : Johnson & Johnson: Revenue Share, 2020
Figure 35 : Bayer AG: Revenue Share, 2020
Figure 36 : Pfizer, Inc.: Revenue Share, 2020
Figure 37 : GlaxoSmithKline Plc.: Revenue Share, 2020
Figure 38 : United Therapeutics Corporation: Revenue Share, 2020
Figure 39 : Gilead Sciences, Inc.: Revenue Share, 2020
Figure 40 : Bristol-Myers Squibb Company: Revenue Share, 2020
Figure 41 : Merck & Co. Inc.: Revenue Share, 2020
Figure 42 : Daiichi Sankyo Company Limited: Revenue Share, 2020
Figure 43 : Eli Lilly and Company: Revenue Share, 2020

Pulmonary Arterial Hypertension Market

Single User License: $5500

* Please allow 10 business days for delivery of this report

Enquiry Before Buying

Pulmonary Arterial Hypertension Market

QUICK LINKS

CUSTOMER SERVICES

ADDRESS